Developed in partnership between CU Anschutz Skaggs School of Pharmacy and Pharmaceutical Sciences and The Colorado Chronic Pain Centers of Excellence
This one-hour free virtual educational activity focuses on identifying and responding to regulatory and clinical risks associated with prescribing and dispensing controlled substances. Using real-world DEA enforcement cases, participants will examine “red flags” indicative of potential drug abuse or diversion, understand the legal concept of corresponding responsibility under 21 C.F.R. § 1306.04(a), and review prescribing and dispensing trends that have led to DEA registration revocations for prescribers and pharmacies alike. The program emphasizes the importance of interdisciplinary collaboration in mitigating risk, promoting compliance, and supporting patient-centered care when managing controlled substances, while offering participants the opportunity to apply these lessons directly to clinical practice.
Objectives:
- Identify “red flags” indicative of drug abuse or diversion that could result in 21 C.F.R. § 1306.04(a) violations if not resolved
- Recognize prescribing trends that have resulted in revocation of DEA registrations for both prescribers and pharmacies
- Describe “corresponding responsibility” and its impact on both pharmacists and prescribers
- Employ effective interdisciplinary collaboration as part of a patient-centered care approach when prescribing and dispensing controlled substances
The CU Anschutz Skaggs School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). This event has been accredited for up to 1.0 contact hours of application-based CPE for pharmacists.
0008-0000-25-152-H08-P
Initial Release Date: 02/03/2026
Planned Expiration Date: 02/03/2029
